What is happening with Novavax?

What is happening with Novavax?

2022-02-25 • Updated

What is Novavax?

Novavax Inc. is an American biotechnology company that develops vaccines to fight severe infectious diseases. By 2020, company scientists have developed experimental vaccines against Ebola, influenza, respiratory syncytial virus (RSV), and other emerging infectious diseases. In 2020, the company refocused its efforts on developing and approving its NVX-CoV2373 COVID-19 vaccine. In addition, Novavax indicated that it recognizes the ongoing need for innovative vaccines in other therapeutic areas and says it has taken steps to ensure that its influenza vaccine is further improved.

Their Nuvaxovid vaccine was approved in the EU at the end of 2021 and in Canada in February 2022 as the fifth COVID-19 vaccine after Pfizer/BioNTech, Moderna, Janssen, and AstraZeneca.

What is Now with Novavax?

Novavax shares (NVAX -7.43%) fell on Wednesday, February 23, in no small part due to analysts' rather sharp cut in their target price. By the time the smoke cleared, the biotech stock was down more than 7% on the day. Now the cost of Novavax stock is around $73.50.

Although many countries have already approved Novavax vaccine, the US is still delaying the approval. Novavax stake is on their vaccine to be an alternative for other current vaccines because it’s based on a well-understood protein-based vaccine platform. They are sure that it can prevent COVID-19 better.

However, last autumn FDA declared that Novavax vaccines produced at US plants were not meeting purity standard. It provoked the decrease in NVAX stocks below $140. Now they improved their vaccine to the FDA standards and they’re waiting for its approval.

Analysts’ Predictions

Novavax’s situation will become more apparent after the company’s results of Q4 and 2021 data in general on February 28.

Apparently, most analysts are optimistic about Novavax, and they expect improvement. However, Investing.com forecasts EPS to be -0.36, and cnn.com supposes that it can range from -5.16 to 7.89. Revenue is forecast to be 453.5M.

After the Q3 release, the Novavax stock fluctuated roughly. The company reported a net loss of $322.4 million, or $4.31 per share, for the third quarter of 2021, compared to a net loss of $197.3 million, or $3.21 per share, for the third quarter of 2020. NVAX revenue in the third quarter of 2021 was $178.8 million compared to $157.0 million in 2020.

2022-02-24_16-34-53.png

Many analysts are now quite optimistic about Novavax. In their view, the company will generate large amounts of revenue over the next two years. The problem is that these analysts are still expecting the FDA approval to go into effect relatively soon. Therefore, if there is any failure in this scenario, their predictions may be wrong.  The main pitfall seems to be the slowing down of pandemic, that can lead to irrelevance of this vaccine.

NVAXH1.png

The stock is currently quite cheap. In addition, it is supported by the 200-week MA at 73.90. It’s also in the area, which has been attracting investor demand since 2020. If the company delivers a good report next week, we may see a double bottom and recovery towards $100.

In the longer term, the stock needs to rise above $100 to get to $140. On the contrary, if the price slides below $70, it may be a start of a big selloff.

NVAXWeekly.png

To sum up, Novavax is at a crossroads, will their statistics help them to improve the situation? Let’s continue to follow the news about this company and we’ll see.

 

Similar

China Stocks are Ready to Move
China Stocks are Ready to Move

China’s stock market performed well last week amid weakening lockdown measures. Traders are becoming bullish and greedy. Should we follow the crowd and buy HK50?

US Stock Market Recovers
US Stock Market Recovers

What happened? US stocks ended sharply higher on Thursday, May 27, after a 7-week losing streak…

Walmart earnings outlook
Walmart earnings outlook

Walmart is one of the biggest retail corporations in the US, with $244 billion in total assets. Does it worth buying amid rising prices and supply concerns that shatter the world economy?

Latest news

What to Trade on July 4-8
What to Trade on July 4-8

Last week was bearish for risky assets such as stocks, oil, gas, and crypto. Will the upcoming week change the situation across the markets? Let’s look at it in detail!

When Will the US Stocks Bear Market Bottom?
When Will the US Stocks Bear Market Bottom?

US stocks have delivered their worst first half of a year in more than 50 years triggered by the Fed's attempt to control inflation and growing concerns about recession.

The Dollar's Strength or Other Currencies' Weakness?
The Dollar's Strength or Other Currencies' Weakness?

The value of the US dollar continues to rise, but is this because of the strength of the dollar itself or just the weakness of the euro, Japanese yen, and British pound? Since the beginning of the year, the US dollar index has been up 8…

Deposit with your local payment systems

Be on top of your game

Data collection notice

FBS maintains a record of your data to run this website. By pressing the “Accept” button, you agree to our Privacy policy.

Callback

A manager will call you shortly.

Change number

Your request is accepted.

A manager will call you shortly.

Next callback request for this phone number
will be available in

If you have an urgent issue please contact us via
Live chat

Internal error. Please try again later

Don’t waste your time – keep track of how NFP affects the US dollar and profit!

Beginner Forex book

Beginner Forex book will guide you through the world of trading.

Beginner Forex book

The most important things to start trading
Enter your e-mail, and we will send you a free Beginner Forex book

Thank you!

We've emailed a special link to your e-mail.
Click the link to confirm your address and get Beginner Forex book for free.

You are using an older version of your browser.

Update it to the latest version or try another one for a safer, more comfortable and productive trading experience.

Safari Chrome Firefox Opera